Skip Navigation

European Heart Journal 2002 23(10):774-787; doi:10.1053/euhj.2001.2979
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by de Windt, L.J
Right arrow Articles by Doevendans, P.A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Windt, L.J
Right arrow Articles by Doevendans, P.A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Reviews

Molecular and genetic aspects of cardiac fatty acid homeostasis in health and disease

L.J de Windta, K Coxb, L Hofstraa and P.A Doevendansa,f1

a Department of Cardiology, Cardiovascular Research Institute Maastricht, University Hospital Maastricht, The Netherlands
b Division of Molecular Cardiovascular Biology, Department of Pediatrics, Children's Hospital Medical Center, Cincinnati, OH, U.S.A.

revised August 7, 2001; accepted August 15, 2001

f1 Correspondence: Pieter A. Doevendans, MD, PhD, FESC, Department of Cardiology, University Hospital Maastricht, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands.

References

  1. Glatz JF, Luiken JJ, van Nieuwenhoven FA, van der Vusse GJ. Molecular mechanism of cellular uptake and intracellular translocation of fatty acids. Prostaglandins Leukot Essent Fatty Acids. 1997;57:3–9[CrossRef][ISI][Medline]
  2. van der Vusse GJ, Glatz JF, Stam HC, Reneman RS. Fatty acid homeostasis in the normoxic and ischemic heart. Physiol Rev. 1992;72:881–940[Free Full Text]
  3. Eaton S, Bartlett K, Pourfarzam M. Mammalian mitochondrial beta-oxidation. Biochem J. 1996;320:345–357[ISI][Medline]
  4. Grynberg A, Demaison L. Fatty acid oxidation in the heart. J Cardiovasc Pharmacol. 1996;28:S11–17[Medline]
  5. Gilman SGG, Waxman SG. Neurobase. La Jolla: Arbor Publishing; 1995.
  6. Chapoy PR, Angelini C, Brown WJ, Stiff JE, Shug AL, Cederbaum SD. Systemic carnitine deficiency—a treatable inherited lipid-storage disease presenting as Reye's syndrome. N Engl J Med. 1980;303:1389–1394[Abstract]
  7. Treem WR, Stanley CA, Finegold DN, Hale DE, Coates PM. Primary carnitine deficiency due to a failure of carnitine transport in kidney, muscle, and fibroblasts. N Engl J Med. 1988;319:1331–1336[ISI][Medline]
  8. Stanley CA, Hale DE, Berry GT, Deleeuw S, Boxer J, Bonnefont JP. Brief report: a deficiency of carnitine-acylcarnitine translocase in the inner mitochondrial membrane. N Engl J Med. 1992;327:19–23[ISI][Medline]
  9. Rhead WJ, Amendt BA, Fritchman KS, Felts SJ. Dicarboxylic aciduria: deficient [1-14C]octanoate oxidation and medium-chain acyl-CoA dehydrogenase in fibroblasts. Science. 1983;221:73–75[Abstract/Free Full Text]
  10. Yamaguchi S, Indo Y, Coates PM, Hashimoto T, Tanaka K. Identification of very-long-chain acyl-CoA dehydrogenase deficiency in three patients previously diagnosed with long-chain acyl-CoA dehydrogenase deficiency. Pediatr Res. 1993;34:111–113[ISI][Medline]
  11. Izai K, Uchida Y, Orii T, Yamamoto S, Hashimoto T. Novel fatty acid beta-oxidation enzymes in rat liver mitochondria. I. Purification and properties of very-long-chain acyl-coenzyme A dehydrogenase. J Biol Chem. 1992;267:1027–1033[Abstract/Free Full Text]
  12. Aoyama T, Souri M, Ueno I. Cloning of human very-long-chain acyl-coenzyme A dehydrogenase and molecular characterization of its deficiency in two patients. Am J Hum Genet. 1995;57:273–283[ISI][Medline]
  13. Aoyama T, Souri M, Ushikubo S. Purification of human very-long-chain acyl-coenzyme A dehydrogenase and characterization of its deficiency in seven patients. J Clin Invest. 1995;95:2465–2473[ISI][Medline]
  14. Hale DE, Batshaw ML, Coates PM. Long-chain acyl coenzyme A dehydrogenase deficiency: an inherited cause of nonketotic hypoglycemia. Pediatr Res. 1985;19:666–671[ISI][Medline]
  15. Uchida Y, Izai K, Orii T, Hashimoto T. Novel fatty acid beta-oxidation enzymes in rat liver mitochondria. II. Purification and properties of enoyl-coenzyme A (CoA) hydratase/3-hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase trifunctional protein. J Biol Chem. 1992;267:1034–1041[Abstract/Free Full Text]
  16. Sims HF, Brackett JC, Powell CK. The molecular basis of pediatric long chain 3-hydroxyacyl-CoA dehydrogenase deficiency associated with maternal acute fatty liver of pregnancy. Proc Natl Acad Sci USA. 1995;92:841–845[Abstract/Free Full Text]
  17. Ijlst L, Ruiter JP, Vreijling J, Wanders RJ. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: a new method to identify the G1528C mutation in genomic DNA showing its high frequency (approximately 90%) and identification of a new mutation (T2198C). J Inherit Metab Dis. 1996;19:165–168[CrossRef][ISI][Medline]
  18. Ushikubo S, Aoyama T, Kamijo T. Molecular characterization of mitochondrial trifunctional protein deficiency: formation of the enzyme complex is important for stabilization of both alpha- and beta-subunits. Am J Hum Genet. 1996;58:979–988[ISI][Medline]
  19. Orii KE, Aoyama T, Souri M. Formation of the enzyme complex in mitochondria is required for function of trifunctional beta-oxidation protein. Biochem Biophys Res Commun. 1996;219:773–777[CrossRef][ISI][Medline]
  20. Loehr JP, Goodman SI, Frerman FE. Glutaric acidemia type II: heterogeneity of clinical and biochemical phenotypes. Pediatr Res. 1990;27:311–315[ISI][Medline]
  21. Wilson GN, de Chadarevian JP, Kaplan P, Loehr JP, Frerman FE, Goodman SI. Glutaric aciduria type II: review of the phenotype and report of an unusual glomerulopathy. Am J Med Genet. 1989;32:395–401[CrossRef][ISI][Medline]
  22. Kamiya M, Eimoto T, Kishimoto H. Glutaric aciduria type II: autopsy study of a case with electron-transferring flavoprotein dehydrogenase deficiency. Pediatr Pathol. 1990;10:1007–1019[Medline]
  23. Yamaguchi S, Orii T, Maeda K, Oshima M, Hashimoto T. A new variant of glutaric aciduria type II: deficiency of beta-subunit of electron transfer flavoprotein. J Inherit Metab Dis. 1990;13:783–786[CrossRef][ISI][Medline]
  24. Coates PM, Hale DE, Finocchiaro G, Tanaka K, Winter SC. Genetic deficiency of short-chain acyl-coenzyme A dehydrogenase in cultured fibroblasts from a patient with muscle carnitine deficiency and severe skeletal muscle weakness. J Clin Invest. 1988;81:171–175[ISI][Medline]
  25. Amendt BA, Greene C, Sweetman L. Short-chain acyl-coenzyme A dehydrogenase deficiency. Clinical and biochemical studies in two patients. J Clin Invest. 1987;79:1303–1309[ISI][Medline]
  26. Wood PA, Amendt BA, Rhead WJ, Millington DS, Inoue F, Armstrong D. Short-chain acyl-coenzyme A dehydrogenase deficiency in mice. Pediatr Res. 1989;25:38–43[ISI][Medline]
  27. Guerra C, Koza RA, Walsh K, Kurtz DM, Wood PA, Kozak LP. Abnormal nonshivering thermogenesis in mice with inherited defects of fatty acid oxidation. J Clin Invest. 1998;102:1724–1731[ISI][Medline]
  28. Kurtz DM, Tian L, Gower BA, Nagy TR, Pinkert CA, Wood PA. Transgenic studies of fatty acid oxidation gene expression in nonobese diabetic mice. J Lipid Res. 2000;41:2063–2070[Abstract/Free Full Text]
  29. Kurtz DM, Rinaldo P, Rhead WJ. Targeted disruption of mouse long-chain acyl-CoA dehydrogenase gene reveals crucial roles for fatty acid oxidation. Proc Natl Acad Sci USA. 1998;95:15592–15597[Abstract/Free Full Text]
  30. Doevendans PAvGW, Laarse A, van Bilsen M. Gene transcription in the cardiovascular system. Cardiologie. 1997;4:221–229
  31. Doevendans PA. Implementation of molecular cardiology into clinical cardiology. Cardiologie. 1999;6:210–217
  32. International Human Genome Sequencing Consortium, Initial sequencing and analysis of the human genome, Nature 2001, 409, 860, 921
  33. Venter JC, Adams MD, Myers EW. Science 2001. The sequence of the human genome;291:1304–1351
  34. Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol. 1991;68:85–89[CrossRef][ISI][Medline]
  35. Dubrey SW, Reaveley DR, Seed M. Risk factors for cardiovascular disease in IDDM. A study of identical twins. Diabetes. 1994;43:831–835[Abstract]
  36. Friedman JJ. Vascular sensitivity and reactivity to norepinephrine in diabetes mellitus. Am J Physiol. 1989;256:H1134–1138[Medline]
  37. Kenno KA, Severson DL. Lipolysis in isolated myocardial cells from diabetic rat hearts. Am J Physiol. 1985;249:H1024–1030[Medline]
  38. Denton RM, Randle PJ. Concentrations of glycerides and phospholipids in rat heart and gastrocnemius muscles. Effects of alloxan-diabetes and perfusion. Biochem J. 1967;104:416–422[ISI][Medline]
  39. Eckel J, Reinauer H. Insulin action on glucose transport in isolated cardiac myocytes: signalling pathways and diabetes-induced alterations. Biochem Soc Trans. 1990;18:1125–1127[ISI][Medline]
  40. Garvey WT, Hardin D, Juhaszova M, Dominguez JH. Effects of diabetes on myocardial glucose transport system in rats: implications for diabetic cardiomyopathy. Am J Physiol. 1993;264:H837–844[ISI][Medline]
  41. Chen V, Ianuzzo CD. Dosage effect of streptozotocin on rat tissue enzyme activities and glycogen concentration. Can J Physiol Pharmacol. 1982;60:1251–1256[ISI][Medline]
  42. Lopashuk GD. Fatty acid metabolism in the heart following diabetes. Chatham JCPD, Forder JR, McNeill JH. The heart in diabetes. Boston: Kluwer Academic Publishers; 1996. p. 215–251
  43. Adams RJ, Cohen DW, Gupte S. In vitro effects of palmitylcarnitine on cardiac plasma membrane Na,K-ATPase, and sarcoplasmic reticulum Ca2+-ATPase and Ca2+ transport. J Biol Chem. 1979;254:12404–12410[Free Full Text]
  44. Kramer JH, Weglicki WB. Inhibition of sarcolemmal Na+-K+-ATPase by palmitoyl carnitine: potentiation by propranolol. Am J Physiol. 1985;248:H75–81[Medline]
  45. Ashavaid TF, Colvin RA, Messineo FC, MacAlister T, Katz AM. Effects of fatty acids on Na/Ca exchange in cardiac sarcolemmal membranes. J Mol Cell Cardiol. 1985;17:851–861[CrossRef][ISI][Medline]
  46. Dhalla NS, Kolar F, Shah KR, Ferrari R. Effects of some L-carnitine derivatives on heart membrane ATPases. Cardiovasc Drugs Ther. 1991;5:25–30[CrossRef][ISI][Medline]
  47. Orrenius S, McConkey DJ, Bellomo G, Nicotera P. Role of Ca2+ in toxic cell killing. Trends Pharmacol Sci. 1989;10:281–285[CrossRef][Medline]
  48. Corr PB, Gross RW, Sobel BE. Amphipathic metabolites and membrane dysfunction in ischemic myocardium. Circ Res. 1984;55:135–154[Free Full Text]
  49. Nicholl TA, Lopaschuk GD, McNeill JH. Effects of free fatty acids and dichloroacetate on isolated working diabetic rat heart. Am J Physiol. 1991;261:H1053–1059[ISI][Medline]
  50. Rodrigues B, Grassby PF, Battell ML, Lee SY, McNeill JH. Hypertriglyceridemia in experimental diabetes: relationship to cardiac dysfunction. Can J Physiol Pharmacol. 1994;72:447–455[ISI][Medline]
  51. Rosen P, Reinauer H. Inhibition of carnitine palmitoyltransferase 1 by phenylalkyloxiranecarboxylic acid and its influence on lipolysis and glucose metabolism in isolated, perfused hearts of streptozotocin-diabetic rats. Metabolism. 1984;33:177–185[CrossRef][ISI][Medline]
  52. Jennings RB, Ganote CE, Reimer KA. Ischemic tissue injury. Am J Pathol. 1975;81:179–198[Abstract]
  53. Ganote CE, Seabra-Gomes R, Nayler WG, Jennings RB. Irreversible myocardial injury in anoxic perfused rat hearts. Am J Pathol. 1975;80:419–450[Abstract]
  54. van der Vusse GJ, Roemen TH, Prinzen FW, Coumans WA, Reneman RS. Uptake and tissue content of fatty acids in dog myocardium under normoxic and ischemic conditions. Circ Res. 1982;50:538–546[Abstract/Free Full Text]
  55. Li QA, Altschuld RA, Stokes BT. Myocyte deenergization and intracellular free calcium dynamics. Am J Physiol. 1988;255:C162–168[Medline]
  56. Allshire APCP. Cytosolic Ca2+ in hypoxic cardiomyocytes. Piper HMIG. Isolated adult cardiomyocytes. Boca Raton: CRC Press; 1989. p. 287–308
  57. Miyamae M, Camacho SA, Weiner MW, Figueredo VM. Attenuation of postischemic reperfusion injury is related to prevention of [Ca2+]m overload in rat hearts. Am J Physiol. 1996;271:H2145–2153[ISI][Medline]
  58. Leperre A, Millart H, Prevost A, Trenque T, Kantelip JP, Keppler BK. Compared effects of ruthenium red and cis [Ru(NH3)4Cl2]Cl on the isolated ischaemic-reperfused rat heart. Fundam Clin Pharmacol. 1995;9:545–553[ISI][Medline]
  59. Tan ZT. Ruthenium red, ribose, and adenine enhance recovery of reperfused rat heart. Coron Artery Dis. 1993;4:305–309[ISI][Medline]
  60. Stone D, Darley-Usmar V, Smith DR, O'Leary V. Hypoxia-reoxygenation induced increase in cellular Ca2+ in myocytes and perfused hearts: the role of mitochondria. J Mol Cell Cardiol. 1989;21:963–973[CrossRef][ISI][Medline]
  61. Grover GJ, Dzwonczyk S, Sleph PG. Ruthenium red improves postischemic contractile function in isolated rat hearts. J Cardiovasc Pharmacol. 1990;16:783–789[ISI][Medline]
  62. Figueredo VM, Dresdner KP Jr, Wolney AC, Keller AM. Postischaemic reperfusion injury in the isolated rat heart: effect of ruthenium red. Cardiovasc Res. 1991;25:337–342[Abstract/Free Full Text]
  63. Goodwin GW, Taegtmeyer H. Metabolic recovery of isolated working rat heart after brief global ischemia. Am J Physiol. 1994;267:H462–470[Medline]
  64. Taegtmeyer H, Roberts AF, Raine AE. Energy metabolism in reperfused heart muscle: metabolic correlates to return of function. J Am Coll Cardiol. 1985;6:864–870[Abstract]
  65. Lopaschuk GD, Collins-Nakai R, Olley PM. Plasma fatty acid levels in infants and adults after myocardial ischemia. Am Heart J. 1994;128:61–67[CrossRef][ISI][Medline]
  66. Chen ZP, McConell GK, Michell BJ, Snow RJ, Canny BJ, Kemp BE. AMPK signaling in contracting human skeletal muscle: acetyl-CoA carboxylase and NO synthase phosphorylation. Am J Physiol Endocrinol Metab. 2000;279:E1202–1206[Abstract/Free Full Text]
  67. Dagher Z, Ruderman N, Tornheim K, Ido Y. The effect of AMP-activated protein kinase and its activator AICAR on the metabolism of human umbilical vein endothelial cells. Biochem Biophys Res Commun. 1999;265:112–115[CrossRef][ISI][Medline]
  68. Kudo N, Gillespie JG, Kung L. Characterization of 5'AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim Biophys Acta. 1996;1301:67–75[Medline]
  69. Liu B, Clanachan AS, Schulz R, Lopaschuk GD. Cardiac efficiency is improved after ischemia by altering both the source and fate of protons. Circ Res. 1996;79:940–948[Abstract/Free Full Text]
  70. Liu B, el Alaoui-Talibi Z, Clanachan AS, Schulz R, Lopaschuk GD. Uncoupling of contractile function from mitochondrial TCA cycle activity and MVO2 during reperfusion of ischemic hearts. Am J Physiol. 1996;270:H72–80[ISI][Medline]
  71. Dobsak P, Courderot-Masuyer C, Zeller M. Antioxidative properties of pyruvate and protection of the ischemic rat heart during cardioplegia. J Cardiovasc Pharmacol. 1999;34:651–659[CrossRef][ISI][Medline]
  72. Liu Q, Clanachan AS, Lopaschuk GD. Acute effects of triiodothyronine on glucose and fatty acid metabolism during reperfusion of ischemic rat hearts. Am J Physiol. 1998;275:E392–399[Medline]
  73. Lopaschuk GD, Saddik M. The relative contribution of glucose and fatty acids to ATP production in hearts reperfused following ischemia. Mol Cell Biochem. 1992;116:111–116[CrossRef][ISI][Medline]
  74. McVeigh JJ, Lopaschuk GD. Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts. Am J Physiol. 1990;259:H1079–1085[ISI][Medline]
  75. Mochizuki S, Neely JR. Energy metabolism during reperfusion following ischemia. J Physiol. 1980;76:805–812
  76. Lopaschuk G. Regulation of carbohydrate metabolism in ischemia and reperfusion. Am Heart J. 2000;139:S115–119[CrossRef][ISI][Medline]
  77. Lopaschuk GD, McNeil GF, McVeigh JJ. Glucose oxidation is stimulated in reperfused ischemic hearts with the carnitine palmitoyltransferase 1 inhibitor, Etomoxir. Mol Cell Biochem. 1989;88:175–179[ISI][Medline]
  78. Liu Y, Rosenthal RE, Starke-Reed P, Fiskum G. Inhibition of postcardiac arrest brain protein oxidation by acetyl-L-carnitine. Free Radic Biol Med. 1993;15:667–670[CrossRef][ISI][Medline]
  79. Madden MC, Wolkowicz PE, Pohost GM, McMillin JB, Pike MM. Acylcarnitine accumulation does not correlate with reperfusion recovery in palmitate-perfused rat hearts. Am J Physiol. 1995;268:H2505–2512[Medline]
  80. Coleman GM, Gradinac S, Taegtmeyer H, Sweeney M, Frazier OH. Efficacy of metabolic support with glucose-insulin-potassium for left ventricular pump failure after aortocoronary bypass surgery. Circulation. 1989;80:I91–96[Medline]
  81. Gradinac S, Coleman GM, Taegtmeyer H, Sweeney MS, Frazier OH. Improved cardiac function with glucose-insulin-potassium after aortocoronary bypass grafting. Ann Thorac Surg. 1989;48:484–489[Abstract]
  82. Ceremuzynski L, Budaj A, Czepiel A. Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: results of a randomized multicenter Pol-GIK trial. Cardiovasc Drugs Ther. 1999;13:191–200[CrossRef][ISI][Medline]
  83. De Windt LJ, Reneman RS, van der Vusse GJ, van Bilsen M. Phospholipase A2-mediated hydrolysis of cardiac phospholipids: the use of molecular and transgenic techniques. Mol Cell Biochem. 1998;180:65–73[CrossRef][ISI][Medline]
  84. Post JA, Langer GA, Op den Kamp JA, Verkleij AJ. Phospholipid asymmetry in cardiac sarcolemma. Analysis of intact cells and ‘gas-dissected’ membranes. Biochim Biophys Acta. 1988;943:256–266[Medline]
  85. van Bilsen M, van der Vusse GJ, Willemsen PH, Coumans WA, Roemen TH, Reneman RS. Lipid alterations in isolated, working rat hearts during ischemia and reperfusion: its relation to myocardial damage. Circ Res. 1989;64:304–314[Abstract/Free Full Text]
  86. Chien KR, Han A, Sen A, Buja LM, Willerson JT. Accumulation of unesterified arachidonic acid in ischemic canine myocardium. Relationship to a phosphatidylcholine deacylation-reacylation cycle and the depletion of membrane phospholipids. Circ Res. 1984;54:313–322[Abstract/Free Full Text]
  87. van Bilsen M, van der Vusse GJ. Phospholipase-A2-dependent signalling in the heart. Cardiovasc Res. 1995;30:518–529[CrossRef][ISI][Medline]
  88. van Bilsen M, van der Vusse GJ, Willemsen PH, Coumans WA, Roemen TH, Reneman RS. Effects of nicotinic acid and mepacrine on fatty acid accumulation and myocardial damage during ischemia and reperfusion. J Mol Cell Cardiol. 1990;22:155–163[CrossRef][ISI][Medline]
  89. Jans SW, Willems J, van Bilsen M, Reutelingsperger CP, van der Vusse GJ. Phospholipid degradation in energy-deprived cardiac myocytes: does annexin V play a role? J Mol Cell Cardiol. 1997;29:1401–1410[CrossRef][ISI][Medline]
  90. van der Vusse GJ, van Bilsen M, Reneman RS. Ischemia and reperfusion induced alterations in membrane phospholipids: an overview. Ann NY Acad Sci. 1994;723:1–14[CrossRef][ISI][Medline]
  91. Jones RL, Miller JC, Hagler HK, Chien KR, Willerson JT, Buja LM. Association between inhibition of arachidonic acid release and prevention of calcium loading during ATP depletion in cultured rat cardiac myocytes. Am J Pathol. 1989;135:541–556[Abstract]
  92. Chien KR, Sen A, Reynolds R. Release of arachidonate from membrane phospholipids in cultured neonatal rat myocardial cells during adenosine triphosphate depletion. Correlation with the progression of cell injury. J Clin Invest. 1985;75:1770–1780[ISI][Medline]
  93. Gunn MD, Sen A, Chang A, Willerson JT, Buja LM, Chien KR. Mechanisms of accumulation of arachidonic acid in cultured myocardial cells during ATP depletion. Am J Physiol. 1985;249:H1188–1194[Medline]
  94. Sen A, Buja LM, Willerson JT, Chien KR. Membrane phospholipid metabolism during myocardial ischaemia: past, present and future. Basic Res Cardiol. 1987;82:121–125
  95. De Windt LJ, Willems J, Coumans WA. The ischemic-reperfused isolated working mouse heart: membrane damage and type IIA secretory phospholipase A2. Am J Physiol. 2001;280:H2572–H2580
  96. Bevers EM, Comfurius P, Dekkers DW, Zwaal RF. Lipid translocation across the plasma membrane of mammalian cells. Biochim Biophys Acta. 1999;1439:317–330[Medline]
  97. Martin SJ, Reutelingsperger CP, McGahon AJ. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med. 1995;182:1545–1556[Abstract/Free Full Text]
  98. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood. 1997;89:1121–1132[Free Full Text]
  99. Bratton DL, Fadok VA, Richter DA, Kailey JM, Guthrie LA, Henson PM. Appearance of phosphatidylserine on apoptotic cells requires calcium-mediated nonspecific flip-flop and is enhanced by loss of the aminophospholipid translocase. J Biol Chem. 1997;272:26159–26165[Abstract/Free Full Text]
  100. van Engeland M, Kuijpers HJ, Ramaekers FC, Reutelingsperger CP, Schutte B. Plasma membrane alterations and cytoskeletal changes in apoptosis. Exp Cell Res. 1997;235:421–430[CrossRef][ISI][Medline]
  101. Reutelingsperger CP, van Heerde WL. Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol Life Sci. 1997;53:527–532[CrossRef][ISI][Medline]
  102. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994;84:1415–1420[Abstract/Free Full Text]
  103. Dumont EA, Hofstra L, van Heerde WL. Cardiomyocyte death induced by myocardial ischemia and reperfusion : measurement with recombinant human annexin-V in a mouse model. Circulation. 2000;102:1564–1568[Abstract/Free Full Text]
  104. Hofstra L, Liem IH, Dumont EA. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet. 2000;356:209–212[CrossRef][ISI][Medline]
  105. Corr PB, Cain ME, Witkowski FX, Price DA, Sobel BE. Potential arrhythmogenic electrophysiological derangements in canine Purkinje fibers induced by lysophosphoglycerides. Circ Res. 1979;44:822–832[Abstract/Free Full Text]
  106. DaTorre SD, Creer MH, Pogwizd SM, Corr PB. Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart. J Mol Cell Cardiol. 1991;23:11–22[ISI][Medline]
  107. Man RY, Kinnaird AA, Bihler I, Choy PC. The association of lysophosphatidylcholine with isolated cardiac myocytes. Lipids. 1990;25:450–454[ISI][Medline]
  108. Sedlis SP, Corr PB, Sobel BE, Ahumada GG. Lysophosphatidyl choline potentiates Ca2+ accumulation in rat cardiac myocytes. Am J Physiol. 1983;244:H32–38[ISI][Medline]
  109. Woodley SL, Ikenouchi H, Barry WH. Lysophosphatidylcholine increases cytosolic calcium in ventricular myocytes by direct action on the sarcolemma. J Mol Cell Cardiol. 1991;23:671–680[CrossRef][ISI][Medline]
  110. Pitts BJ, Okhuysen CH. Effects of palmitoyl carnitine and LPC on cardiac sarcolemmal Na+-K+-ATPase. Am J Physiol. 1984;247:H840–846[ISI][Medline]
  111. Undrovinas AI, Fleidervish IA, Makielski JC. Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine. Circ Res. 1992;71:1231–1241[Abstract/Free Full Text]
  112. Magishi K, Kimura J, Kubo Y, Abiko Y. Exogenous lysophosphatidylcholine increases non-selective cation current in guinea-pig ventricular myocytes. Pflugers Arch. 1996;432:345–350[CrossRef][ISI][Medline]
  113. Xiao YF, Kang JX, Morgan JP, Leaf A. Blocking effects of polyunsaturated fatty acids on Na+ channels of neonatal rat ventricular myocytes. Proc Natl Acad Sci USA. 1995;92:11000–11004[Abstract/Free Full Text]
  114. Xiao YF, Gomez AM, Morgan JP, Lederer WJ, Leaf A. Suppression of voltage-gated L-type Ca2+ currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes. Proc Natl Acad Sci USA. 1997;94:4182–4187[Abstract/Free Full Text]
  115. Xiao YF, Wright SN, Wang GK, Morgan JP, Leaf A. Fatty acids suppress voltage-gated Na+ currents in HEK293t cells transfected with the alpha-subunit of the human cardiac Na+ channel. Proc Natl Acad Sci USA. 1998;95:2680–2685[Abstract/Free Full Text]
  116. Kang JX, Leaf A. Prevention of fatal cardiac arrhythmias by polyunsaturated fatty acids. Am J Clin Nutr. 2000;71:202S–207S[Abstract/Free Full Text]
  117. Burr ML, Fehily AM, Gilbert JF. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989;2:757–761[ISI][Medline]
  118. de Lorgeril M, Renaud S, Mamelle N. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 1994;343:1454–1459[CrossRef][ISI][Medline]
  119. Siscovick DS, Raghunathan TE, King I. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA. 1995;274:1363–1367[Abstract]
  120. Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, Moshiri M. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival—4. Cardiovasc Drugs Ther. 1997;11:485–491[CrossRef][ISI][Medline]
  121. Christensen JH, Korup E, Aaroe J. Fish consumption, n-3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction. Am J Cardiol. 1997;79:1670–1673[CrossRef][ISI][Medline]
  122. Albert CM, Hennekens CH, O'Donnell CJ. Fish consumption and risk of sudden cardiac death. JAMA. 1998;279:23–28[Abstract/Free Full Text]
  123. Power GWNE. Dietary fatty acids influence the activity and metabolic control of mitochondrial carnitine palmitoyltransferase I in rat heart and skeletal muscle. J Nutr. 1997;127:2142–2150[Abstract/Free Full Text]
  124. van Bilsen M, de Vries JE, van der Vusse GJ. Long-term effects of fatty acids on cell viability and gene expression of neonatal cardiac myocytes. Prostaglandins Leukot Essent Fatty Acids. 1997;57:39–45[CrossRef][ISI][Medline]
  125. van der Lee KA, Vork MM, De Vries JE. Long-chain fatty acid-induced changes in gene expression in neonatal cardiac myocytes. J Lipid Res. 2000;41:41–47[Abstract/Free Full Text]
  126. Osumi T, Wen JK, Hashimoto T. Two cis-acting regulatory sequences in the peroxisome proliferator-responsive enhancer region of rat acyl-CoA oxidase gene. Biochem Biophys Res Commun. 1991;175:866–871[CrossRef][ISI][Medline]
  127. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5+ flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 1992;11:433–439[ISI][Medline]
  128. Zhang B, Marcus SL, Sajjadi FG. Identification of a peroxisome proliferator-responsive element upstream of the gene encoding rat peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase. Proc Natl Acad Sci USA. 1992;89:7541–7545[Abstract/Free Full Text]
  129. Gearing KL, Gottlicher M, Teboul M, Widmark E, Gustafsson JA. Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci USA. 1993;90:1440–1444[Abstract/Free Full Text]
  130. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature. 1992;358:771–774[CrossRef][Medline]
  131. Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol. 1999;10:245–257[CrossRef][ISI][Medline]
  132. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol. 2000;129:823–834[CrossRef][ISI][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
F. Eefting, B. Rensing, J. Wigman, W. J. Pannekoek, W. M. Liu, M. J. Cramer, D. J Lips, and P. A Doevendans
Role of apoptosis in reperfusion injury
Cardiovasc Res, February 15, 2004; 61(3): 414 - 426.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by de Windt, L.J
Right arrow Articles by Doevendans, P.A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Windt, L.J
Right arrow Articles by Doevendans, P.A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?